Newly Released OpenClinica 3.1 Will be Demonstrated at the Drug Information Association Annual Meeting
OpenClinica, LLC is pleased to announce the production release of OpenClinica 3.1, the culmination of 18 months of effort for the growing open source electronic data capture software company. OpenClinica enhances the productivity of clinical trials through highly capable, flexible, commercial open source software. The software is freely available for download at https://community.openclinica.com.
“OpenClinica 3.1 is the most capable, easy to use, and flexible release to date,” said Cal Collins, OpenClinica’s CEO. “The software improves the efficiency of data managers, monitors, and site users to capture and clean data, provides a way to easily customize data extract formats, includes an expanded web services interface to facilitate interoperability with other systems and data sources, and supports dynamic skip logic in case report forms. Both the Enterprise and Community editions of the software have been heavily tested at OpenClinica and by beta users in the open source community over the past six months, and we are pleased to release the technology for general production use.”
OpenClinica will hold demonstrations of the new software and answer questions at the Drug Information Association’s 47th Annual Meeting this month in Chicago (booth #1843), which kicks-off on June 19th.
Sound technology and a model that makes it easy to both adopt and adapt has propelled the growth of OpenClinica. Earlier this month, the company released statistics showing that over the last year, the number of clinical trials powered by OpenClinica grew by 250 percent. Collins says there are over 400 active production implementations worldwide and a single implementation can support multiple trials.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
